Researchers at Boston Children’s Hospital have published a discovery in Nature detailing receptor-free signal transduction in Toll-like receptors. The finding reveals that these receptors assemble and release signaling proteins to form inflammatory myddosomes, challenging decades of immunological dogma and offering new targets for autoimmune disease treatments.
Challenging Dogma: The Discovery of Receptor-Free Signaling
For decades, the standard model of cell biology rested on a straightforward premise: receptors detect environmental cues—such as infections, damaged cells, or other organisms—and bind to cytoplasmic proteins to trigger cellular changes like inflammation. That framework has guided biomedical research since the discovery of Toll-like receptors as drivers of immunity in the 1990s, when the identification of evolutionarily conserved NF-κB family transcription factors as regulators of anti-microbial responses in Drosophila melanogaster led to the suggestion that similar defense pathways operate in mammals, alongside early studies noting that Toll-like receptors were the first family of proteins to fulfill Janeway’s predictions of Pattern Recognition Receptors (PRRs).
Now, a team led by researchers at Boston Children’s Hospital has identified a new, receptor-free means of signal transduction. In findings published in Nature, scientists observed that Toll-like receptors assemble during inflammation and then release signaling proteins rather than holding onto them. Counter to long-standing assumptions, this receptor-free state is not an endpoint or an error; it is a strict biological requirement.
How Myddosomes Drive Inflammation Without Receptors
The newly detailed mechanism centers on the formation of myddosomes, which are key inflammation-stimulatory organelles. According to the research, the release of signaling proteins from TLRs is essential for these structures to assemble and induce inflammatory gene expression.
Without that receptor release step, myddosomes cannot form. This process upends the traditional view that the receptor must remain bound to mediate downstream effects. Instead, the cell instigates functional changes without the receptor acting as the continuous middleman.
Toll-like receptors themselves comprise a small family of proteins that serve as early determinants of immune activation. Humans possess 10 members (TLR1 through TLR10) according to frontiersin.org (while pmc.ncbi.nlm.nih.gov notes the family comprises these proteins and highlights historical genetic analysis by groups including Poltorak and colleagues identifying bacterial lipopolysaccharide), while mice carry 12 (TLR1 through TLR9, TLR11 through TLR13), split between cell surface locations (such as TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) and intracellular compartments such as endosomes, lysosomes, or endolysosomes (including TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13). These receptors recognize pathogen-associated molecular patterns (PAMPs) from microbes as well as damage-associated molecular patterns (DAMPs) from injured cells, initiating cascades that rely on adaptor proteins like MyD88 and TRIF.
Explaining Past Therapeutic Failures in Autoimmune Disease
The discovery of receptor-free signaling helps explain a persistent hurdle in drug development. Over the years, pharmaceutical efforts aimed to suppress TLR activity by interfering directly with the receptors themselves, yielding little clinical success.
Because the signaling action ultimately operates free of the receptor, blocking the receptor leaves the downstream assembly mechanics intact. Shifting the therapeutic bullseye from the receptor to the myddosome changes the calculus for drug designers.
“New strategies to manipulate the TLR pathway, central to so many aspects of inflammation, are now possible.”
Jonathan Kagan, Director of Basic Research and Shwachman Chair in Gastroenterology at Boston Children’s Hospital
Preclinical Evidence and What Comes Next
The research team has already moved beyond theoretical models. Investigators have gathered pharmacological evidence showing that disrupting myddosomes directly—rather than attempting to block receptor function—successfully resolved inflammation in mice.
The immediate objective for researchers is the development of new classes of small molecules capable of manipulating myddosomes. If translated successfully, these compounds could provide a therapeutic avenue for autoimmune diseases and other inflammatory conditions where conventional receptor antagonists have failed.